Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer

Journal of the National Cancer Institute

Volumn 106, Issue 4, 2014, Pages

  Sanoff, Hanna K ^a,b   Deal, Allison M ^a   Krishnamurthy, Janakiraman ^a,b   Torrice, Chad ^a,b   Dillon, Patrick ^d   Sorrentino, Jessica ^a   Ibrahim, Joseph G ^a,c   Jolly, Trevor A ^b   Williams, Grant ^b   Carey, Lisa A ^a,b   Drobish, Amy ^a   Gordon, Brittaney Belle ^a   Alston, Shani ^a   Hurria, Arti ^e   Kleinhans, Karin ^f   Rudolph, K Lenhard ^f   Sharpless, Norman E ^a,b   Muss, Hyman B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 7; MESSENGER RNA; MOLECULAR MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; TAXANE DERIVATIVE; VASCULOTROPIN A; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTOKINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CELL AGING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE DENSIFICATION; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; ANIMAL; BLOOD; BREAST TUMOR; CANCER STAGING; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE; TELOMERE;

ADP-RIBOSYLATION FACTORS; ADULT; AGED; ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL AGING; CROSS-SECTIONAL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOKINES; FEMALE; HUMANS; MICE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TELOMERE;

EID: 84898927522     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju057     Document Type: Article

References (51)

1. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-2765.
2. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9):2338-2366.
3. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.
4. Chow EJ, Liu W, Srivastava K, et al. Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report. Pediatr Blood Cancer. 2013;60(1):110-115.
5. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806-1816.
6. Krull KR, Sabin ND, Reddick WE, et al. Neurocognitive function and CNS integrity in adult survivors of childhood hodgkin lymphoma. J Clin Oncol. 2012;30(29):3618-3624.
7. Ness KK, Hudson MM, Pui CH, et al. Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer. 2012;118(3):828-838.
8. Pachman DR, Barton DL, Swetz KM, et al. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30(30):3687-3696.
9. Fried L P, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M156.
10. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol. 2007;8(9):703-713.
11. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547-556.
12. Zindy F, Quelle DE, Roussel MF, et al. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene. 1997;15(2):203-211.
13. Krishnamurthy J, Torrice C, Ramsey MR, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004;114(9):1299-1307.
14. Liu Y, Sanoff HK, Cho H, et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009;8(4):439-448.
15. Krishnamurthy J, Ramsey MR, Ligon KL, et al. p16(INK4a) induces an age-dependent decline in islet regenerative potential. Nature. 2006;443(7110):453-457.
16. Molofsky AV, Slutsky SG, Joseph NM, et al. Increasing p16(INK4a) expression decreases forebrain progenitors and neurogenesis during ageing. Nature. 2006;443(7110):448-452.
17. Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16(INK4a). Nature. 2006;443(7110):421-426.
18. Liu Y, Johnson SM, Fedoriw Y, et al. Expression of p16(INK4a) prevents cancer and promotes aging in lymphocytes. Blood. 2011;117(12):3257-3267.
19. Signer RA, Montecino-Rodriguez E, Witte ON, et al. Aging and cancer resistance in lymphoid progenitors are linked processes conferred by p16Ink4a and Arf. Genes Dev. 2008;22(22):3115-3120.
20. Jeck WR, Siebold A P, Sharpless NE. Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell. 2012;11(5):727-731.
21. Berent-Maoz B, Montecino-Rodriguez E, Signer RA, et al. Fibroblast growth factor-7 partially reverses murine thymocyte progenitor aging by repression of Ink4a. Blood. 2012;119(24):5715-5721.
22. Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232- 236.
23. Chen H, Gu X, Liu Y, et al. PDGF signalling controls age-dependent proliferation in pancreatic beta-cells. Nature. 2011;478(7369):349-355.
24. Valdes AM, Andrew T, Gardner J P, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486):662-664.
25. Mirabello L, Huang WY, Wong JY, et al. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell. 2009;8(4):405-413.
26. Song Z, von Figura G, Liu Y, et al. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell. 2010;9(4):607-615.
27. Coppe J P, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118.
28. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proin-flammatory state. Blood. 2005;105(6):2294-2299.
29. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(3):242-248.
30. Taaffe DR, Harris TB, Ferrucci L, et al. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci. 2000;55(12):M709-M715.
31. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10(3):319-329.
32. Maggio M, Guralnik JM, Longo DL, et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006;61(6):575-584.
33. Nelson JA, Krishnamurthy J, Menezes P, et al. Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell. 2012;11(5):916-918
34. American Joint Committee on Cancer (AJCC) C, Illinois. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
35. Burd CE, Sorrentino JA, Clark KS, et al. Monitoring tumorigen-esis and senescence in vivo with a p16(INK4a)-luciferase model. Cell.2013;152(1-2):340- 351.
36. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 2002;16(9):935-942.
37. Herbig U, Ferreira M, Condel L, et al. Cellular senescence in aging primates. Science. 2006;311(5765):1257.
38. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-1439.
39. Coppe J P, Kauser K, Campisi J, et al. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem. 2006;281(40):29568-29574.
40. Nielsen G P, Stemmer-Rachamimov AO, Shaw J, et al. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest. 1999;79(9):1137-1143.
41. Muezzinler A, Zaineddin AK, Brenner H. A systematic review of leukocyte telomere length and age in adults. Ageing Res Rev. 2013;12(2):509-519.
42. Hager K, Machein U, Krieger S, et al. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging. 1994;15(6):771-772.
43. Longo DL. Telomere dynamics in aging: much ado about nothing? J Gerontol A Biol Sci Med Sci. 2009;64(9):963-964.
44. Schroder CP, Wisman GB, de Jong S, et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer. 2001;84(10):1348-1353.
45. Ben-Josef E, Schipper M, Francis IR, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1166-1171.
46. Szyper-Kravitz M, Uziel O, Shapiro H, et al. Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34+ haematopoietic cells and may prevent telomere attrition after chemotherapy. Br J Haematol. 2003;120(2):329-336.
47. Engelhardt M, Kumar R, Albanell J, et al. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood. 1997;90(1):182-193.
48. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003;63(11):2705-2715.
49. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245-270.
50. Rossi DJ, Bryder D, Seita J, et al. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature. 2007;447(7145):725-729.
51. Early Breast Cancer Trialists' Collaborative Group, Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet. 2012;379(9814):432-444.